Cambridge Enterprise, the commercialisation unit of Cambridge University, has announced the institution could earn up to £10.7m ($17.6m) from the $95m sale of medtech BlueGnome to US biotech Illumina. The university has already made £7.7m from the deal, but another £3m could be earned if milestones are met by BlueGnome. The proceeds from the deal…
Cambridge to land $17.6m windfall
Jan 21, 2014 •
LEADERSHIP SOCIETYInforming, connecting, and transforming the global corporate venture capital ecosystem.
The Global Corporate Venturing (GCV) Leadership Society’s mission is to help bridge the different strengths and ambitions of investors across industry sectors, geography, structure, and their returns.
More featured content
Resistance is futile: seven superconductor companies that want to change the world
From healthcare to fusion to quantum computing to space, superconductors have the potential to revolutionise the world. And the technology is finally ready to commercialise.
UK universities urged to lower spinout stakes
A new report recommends stakes of less than 25% but fails to address the issue of access to early-stage capital.
Feb 7, 2024
Mar 14, 2024
Monterey, CA (USA)
Jun 26, 2024